Metraipolis › archive › dc_8a50e91e6283

TNFR2 Agonism: Basic Science and Promising Treatment for Multiple Sclerosis and Related Diseases — Europe PMC PMID:40869160

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40869160
DOI
10.3390/ijms26167839
License (as archived)
solo-consultazione
Archived
2026-11-10T15:22:08.793Z
SHA-256 of the archived text
9dc2169bf06f13c4666532023a5e1da5eb2b22cd34239c3240f9a087b4c2aec2
Stable URL of this page
https://metraipolis.com/documento/dc_8a50e91e6283

How to cite

TNFR2 Agonism: Basic Science and Promising Treatment for Multiple Sclerosis and Related Diseases — Europe PMC PMID:40869160 — Europe PMC (en), https://europepmc.org/article/MED/40869160 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8a50e91e6283 (Metraipolis archive dc_8a50e91e6283, sha256 9dc2169bf06f13c4666532023a5e1da5eb2b22cd34239c3240f9a087b4c2aec2)
BibTeX
@misc{dc8a50e91e6283,
  title = {TNFR2 Agonism: Basic Science and Promising Treatment for Multiple Sclerosis and Related Diseases — Europe PMC PMID:40869160},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40869160},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8a50e91e6283; sha256 9dc2169bf06f13c4666532023a5e1da5eb2b22cd34239c3240f9a087b4c2aec2},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40869160. Agents can read the archived copy with the MCP tool read_document.